Literature DB >> 18667172

Patient clinical factors influencing use of hysterectomy in New York, 2001-2005.

Herbert Gretz1, William H Bradley, Konstantin Zakashansky, Farr Nezhat, Jamal Rahaman, Linus Chuang, Deborah Loeb Bohren, Kenneth Kreiger, Elizabeth Rubin, Alan Sokolow.   

Abstract

OBJECTIVE: To determine the effect of patient clinical factors on the utilization of hysterectomy and alternatives of hysterectomy. STUDY
DESIGN: The database of Empire Blue Cross Blue Shield was abstracted for all claims relating to a hysterectomy procedure or a hysterectomy-associated diagnosis during the 48 consecutive months of May 2001-April 2005. Two hundred ninety-five thousand one hundred forty-eight claim lines were abstracted and analyzed by CPT and diagnostic grouping codes.
RESULTS: One thousand nine hundred seventy-two hysterectomies were performed during the time analyzed, and 5,077 hysterectomy alternatives. The mean age of all patients encountered was 39.1 years. Patients undergoing a hysterectomy alternative or hysterectomy had mean ages of 46.0 and 49.7 years, respectively. Abnormal bleeding was associated with the most encounters, while leiomyomata was associated with the most hysterectomies performed.
CONCLUSION: Patients who undergo hysterectomy are, on average, older than those undergoing office management or hysterectomy alternatives. Procedures are most commonly associated with diagnosis of bleeding, leiomyomata, or cancer. Bleeding typically results in a hysterectomy alternative, while leiomyomata has the highest association with hysterectomy.

Entities:  

Mesh:

Year:  2008        PMID: 18667172     DOI: 10.1016/j.ajog.2008.05.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Nationwide use of laparoscopic hysterectomy compared with abdominal and vaginal approaches.

Authors:  Vanessa L Jacoby; Amy Autry; Gavin Jacobson; Robert Domush; Sanae Nakagawa; Alison Jacoby
Journal:  Obstet Gynecol       Date:  2009-11       Impact factor: 7.661

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.